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The sequence-specific modification of genomic DNA is an 
important  goal  of  gene-  and  stem  cell-based  therapies.1,2 
Since the demonstration that transgenic animals could be 
generated  by  targeting  specific  genomic  loci  by  homolo-
gous recombination,3,4 numerous investigators have focused 
on developing gene-targeting strategies that will efficiently 
and  reliably  correct  mutations  in  genomic  DNA.1,5–7 Three 
papers have recently appeared,8–10 including one in the early 
online edition of Molecular Therapy, that describe an effi-
cient, helper-dependent adenovirus (HDAV)-based system 
for  targeted  modification  of  specific  sequences  in  human 
embryonic  and  induced  pluripotent  stem  (hES  and  hiPS, 
respectively) cells. These studies lay the foundation not only 
for the development of isogenic human pluripotent stem cells 
for basic research, but also for the generation of therapeutic, 
autologous, patient-derived stem cells in which the disease-
  causing mutation has been corrected.
The derivation of hES cells in 199811 and hiPS cells in 
200712,13  prompted  researchers  to  develop  approaches  to 
introduce sequence-specific genomic modifications into the 
DNA of these pluripotent cells. Early reports showed some 
promise and used classical gene-targeting vectors,14,15 but 
few publications indicated that this strategy was sufficiently 
robust in pluripotent cells. By 2009, relying on the observa-
tion  that  double-strand  breaks  (DSBs)  enhance  homolo-
gous recombination in mammalian cells,16–18 several groups 
reported the successful targeting of multiple genes in hES 
and hiPS cell lines by combining the expression of zinc-finger 
nucleases (ZFNs) with the delivery of homologous plasmid19,20 
or with oligo/polynucleotide donor DNA.7,21 ZFNs5,6 and more 
recently,  the  transcription  activator-like  effort  nucleases 
(TALENs)22,23 have provided researchers the tools to carry-
out “genetic surgery” at specific genomic loci based on an 
increased efficiency of homologous recombination.19,20 A pri-
mary concern with these targeted endonuclease systems is 
their potential to generate nonspecific off-site cleavage that 
could destabilize the genome of the targeted cells.5,21
The  report  in  Molecular  Therapy  by  Aizawa  et  al.,8 
describes the use of an HDAV system to deliver sequences 
essentially  homologous  to  the  genomic  target  and  both 
overcomes  some  of  the  limitations  of  more  classical 
approaches to homologous recombination as well as mini-
mizes the potential for random integration into the genomic 
DNA. The HDAV system is effectively a “gutted” adenovi-
rus from which all viral genes have been deleted, retaining 
only those viral sequences required for direct packaging of 
the DNA vector into the virus capsid.24 The HDAV vector is 
packaged by cotransfection into a producer mammalian cell 
line with a “helper” virus genome that contains all of the viral 
genes necessary for vector replication, capsid production, 
and vector packaging.25 An advantage of the recombinant 
HDAV vector is that it can accommodate between 25–35 
kb of DNA, as opposed to, for example, the ~4.7 kb limita-
tion imposed on the adeno-associated virus (AAV) system. 
This capacity is more than sufficient to accommodate large 
homologous regions of genomic DNA and drug selectable 
markers  to  stimulate  homologous  recombination  and  to 
allow enrichment of cells that have been targeted.
Because  certain  viruses  have  evolved  precise  mecha-
nisms to deliver DNA to the nucleus, viral transduction tends 
to be much more efficient than that mediated by chemical or 
physical methods. Recombinant viral vectors also have less 
of a negative effect upon cell viability than nonviral methods 
that disrupt the cellular and nuclear membranes or sequester 
the DNA by binding it too tightly and interfering with deliv-
ery to the nucleus.26,27 Consistent with this, the HDAV sys-
tem described by Aizawa et al.8 appears to give rise to little 
cytotoxicity, exhibits a higher overall efficiency of DNA deliv-
ery  when  compared  to  electroporation  or  chemical-based 
systems, and avoids the degradation and catenation of the 
vector often associated with the latter systems.27 For all prac-
tical purposes, HDAV delivery can be viewed as functionally 
equivalent to nuclear microinjection of DNA. The availability 
of strategies to modify adenovirus vector tropism suggests 
that it might be possible to adapt this strategy to specifically 
target multiple types of cells or tissues.
The study uses a classical “positive–negative selection” 
strategy  to  enrich  for  homologous  recombinants.28  Initial 
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selection for G418 (neomycin) resistance (G418R) enriches 
for  cells  that  have  incorporated  the  recombinant  target-
ing vector somewhere in their genomic DNA. The homolo-
gous  targeting  sequence  is  fused  to  the  herpes  simplex 
virus-  thymidine  kinase  (HSV-TK)  gene,  which  is  lost  dur-
ing homologous recombination. Cells that have undergone 
homologous recombination are thus not sensitive to killing 
by  HSV-TK  activation  following  exposure  to  the  pro-drug, 
gancyclovir (GANC). In contrast, G418R cells containing ran-
dom integrations will retain the HSV-TK gene and will there-
fore be sensitive to GANC-induced killing. The hES or hiPS 
cells were exposed to individual HDAV vectors targeting one 
of five different native genes (HPRT1, LIG1, LIG3, KU80, 
and HB9). HPRT1, LIG1, LIG3, and KU80 are expressed 
genes that are involved in either DNA synthesis (HPRT1) 
or the non-  homologous end-joining (NHEJ) DNA repair pro-
cessing (LIG1, LIG3, and KU80) pathways. The HB9 gene 
is only transcriptionally active in motor neurons and is not 
expressed in pluripotent cells. The absolute gene-targeting 
efficiency ranged from 5.6 × 10−5 to 2 × 10−7 homologous 
recombinants per cell, with relative recombination efficien-
cies ranging from 7% to an impressive 81% of the G418R 
colonies. These results are consistent with what has been 
observed in mouse ES cells and in other somatic cells as 
well as when using ZFN-mediated homologous recombina-
tion and further confirms that the hES and hiPS cells are not 
recalcitrant to vector-mediated homologous recombination. 
Whether the range of efficiency is dependent on the genetic 
target, the cell line or the transcriptional status of the tar-
get gene will require further statistical analysis as well as a 
detailed analysis of the culture conditions at the time of the 
experiment.
HDAV-mediated gene targeting has been recently reported 
by an independent group at other gene targets: the laminin A 
gene (LMNA) in hES and hiPS cells10 and the human β-globin 
gene.9 As with the Aizawa study8 the cells that had undergone 
HDAV-mediated homologous recombination maintained the 
expression of markers diagnostic for hES/hiPS cells, a nor-
mal karyotype, and the capacity to differentiate.9,10
There  are  a  few  caveats  common  to  all  these  studies, 
some of which are inherent to HDAV-based gene targeting. If 
applied in vivo, there is the potential for such vectors to elicit 
an immune response to the adenovirus capsid proteins. This 
is less likely to be an issue for ex vivo applications, since the 
residual capsid proteins would likely be lost over several cell 
divisions. While random integration of intact targeting vec-
tors was not detected in these studies, it is possible that a 
fragmented targeting vector might integrate into the host cell 
genome without detection. While this is beyond the scope of 
the present study and would require extensive sequencing 
analysis, it will be an important issue to address before the 
contemplation of clinical applications.
The possibility of removal of the positive drug selectable 
maker (neomycin gene) was achieved by flanking the latter 
with loxP or FRT sequences. Removal of the neomycin gene 
in some of the homologous recombinant hiPS cell lines was 
achieved by subsequent transfection of the Cre or FLP recom-
binase  to  catalyze  site-specific  recombination  between  the 
loxP or FRT sequences that flank the selectable gene. How-
ever, this process leaves behind some loxP or FRT sequences 
that are sometimes referred to as a footprint or scar. Demon-
strating removal of the drug selectable marker in these cells 
is another important step towards defining protocols that will 
mitigate  potential  risks  associated  with  patient-specific  cell 
lines that could be used for therapeutic purposes. Whether 
the short loxP or FRT DNA footprint will have any detectable 
  biological activity that might compromise the corrected cell 
lines for therapeutic application, remains to be seen.
These studies describe new tools for modifying and editing 
the genomic DNA in an efficient sequence-specific fashion. 
While the therapeutic potential of the HDAV system remains 
to be tested, it is a promising addition to the gene and cell 
therapy toolbox that could facilitate gene targeting for the 
treatment of inherited diseases.1,3
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